Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.30 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.30 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.30 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL876238 | 0.83 | MCHR1 (0.39) | MCHR1HCAR1PDE2AGUCY1B2GUCY1A2 | |
| SCHEMBL875617 | 0.81 | USP7 (0.36) | MCHR1PDE2A | |
| SCHEMBL883609 | 0.75 | KCNQ2 (0.35) | MCHR1GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL875212 | 0.74 | GUCY1B2 (0.34) | MCHR1GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL876018 | 0.73 | PIK3CD (0.37) | MCHR1GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL875143 | 0.69 | KDM4E (0.40) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL14552834 | 0.67 | MAPT (0.40) | — | |
| SCHEMBL14552819 | 0.67 | KMT2A (0.39) | — | |
| SCHEMBL14554136 | 0.65 | ADRA2A (0.36) | — | |
| SCHEMBL875476 | 0.63 | USP7 (0.44) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619202-A1 | PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES | Pfizer Inc (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130184294-A1 | Pyrimidones for Treatment of Potassium Channel Related Diseases | PFIZER INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2012038850-A1 | PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES | PFIZER INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184294-A1 | Pyrimidones for Treatment of Potassium Channel Related Diseases | KCNQ5, KCNQ1, KCNQ3 | MCHR1 1407/4885HCAR1 1427/4885PDE2A 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.